Evolving ways that drug therapy is individualized
2003; Wiley; Volume: 74; Issue: 3 Linguagem: Inglês
10.1016/s0009-9236(03)00189-9
ISSN1532-6535
Autores Tópico(s)Blood disorders and treatments
ResumoClinical Pharmacology & TherapeuticsVolume 74, Issue 3 p. 197-202 Commentary Evolving ways that drug therapy is individualized Marcus M. Reidenberg MD, FACP, Corresponding Author Marcus M. Reidenberg MD, FACP Departments of Pharmacology, Medicine, and Public Health, Weill Medical College of Cornell University, New York, NY, USA Department of Pharmacology, Box 70, Weill Medical College of Cornell University, New York, NY 10021, USA. E-mail: [email protected]Search for more papers by this author Marcus M. Reidenberg MD, FACP, Corresponding Author Marcus M. Reidenberg MD, FACP Departments of Pharmacology, Medicine, and Public Health, Weill Medical College of Cornell University, New York, NY, USA Department of Pharmacology, Box 70, Weill Medical College of Cornell University, New York, NY 10021, USA. E-mail: [email protected]Search for more papers by this author First published: 17 September 2003 https://doi.org/10.1016/S0009-9236(03)00189-9Citations: 6Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1Withering, W. (1979). An account of the foxglove and some of its medical uses. Special edition. Birmingham (AL): Privately printed for the members of the Classics of Medicine Library. 2Dameshek, W. and Colmes, A. (1936). The effect of drugs in the production of agranulocytosis with particular reference to amidopyrine hypersensitivity. J Clin Invest. 15: 85– 97. 3Taussig, H. B. (1963). A study of the German outbreak of phocomelia. JAMA. 180: 1106– 1114. 4Schreiner, G. E. and Maher, J. C. (1965). Drugs and the kidney. Ann N Y Acad Sci. 123: 326– 332. 5Richet, G., Fabre, J., de Freudenreich, J. and Podevin, R. (1966). Drug tolerance of uremic patients. Necessity for a toxicology adapted to visceral insufficiencies [in French]. Presse Med. 74: 2339– 2340. 6Kunin, C. M. (1967). A guide to the use of antibiotics in patients with renal disease. Ann Intern Med. 67: 151– 158. 7Reidenberg, M. M. (1971). Renal function and drug action. Saunders: Philadelphia. 8Wuth, O. (1927). Rational bromide therapy. JAMA. 287: 227– 231. 9Shannon, J. A. (1946). The study of antimalarials and antimalarial activity in the human malarias. Harvey Lectures. 41: 43– 89. 10Buchthal, F., Svensmack, O. and Schiller, P. J. (1960). Clinical and electroencephalographic correlation with serum levels of diphenylhydantoin. Arch Neurol. 2: 624– 630. 11Grahame-Smith, D. G. and Everest, M. S. (1969). Measurement of digoxin in plasma and its use in diagnosis of digoxin intoxication. BMJ. 1: 826– 829. 12Reidenberg, M. M. (1974). Individualization of drug therapy. Med Clin North Am. 58: 905– 1162. 13Kalow, W. (1962). Pharmacogenetics. Saunders: Philadelphia. 14LaDu, B. (1971). Plasma esterase activity and the metabolism of drugs with ester group. Ann N Y Acad Sci. 179: 684– 694. 15Motulsky, A. G., Yoshida, A. and Stamatoyannopoulos, G. (1971). Variants of glucose-6-phosphate dehydrogenase. Ann N Y Acad Sci. 179: 636– 643. 16Price-Evans, D. A. (1993). Genetic factors in drug therapy. Cambridge University Press: Cambridge (UK). 17Kalow, W., Meyer, U. and Tyndale, R. F. (2001). Interethnic differences in drug response. Pharmacogenomics. In: W. Kalow, U. Meyer and R.F. Tyndale (Eds). Dekker: New York. 109– 134. 18Weinshilboum, R. (2001). Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos. 29: 601– 605. 19Diasio, R. B. and Johnson, M. R. (1999). Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res. 5: 2672– 2673. 20Druker, B. J. and Lydon, N. B. (2000). Lessons learned from the development of an Abl tryosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest. 105: 3– 7. 21Calvert, P. M. and Frucht, H. (2002). The genetics of colorectal cancer. Ann Intern Med. 137: 603– 612. 22Hudziak, R. M., Lewis, G. D., Winget, M., Fendly, B. M., Shepard, H. M. and Ulrich, A. (1989). P185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol. 9: 1165– 1172. 23Heaf, P.J.D. (1970). Deaths in asthma: a therapeutic misadventure? Br Med Bull. 26: 245– 247. 24Seppala, H., Klaukka, T., Vuopio-Varkila, J., Muotiala, A., Helenius, H. and Lager, K., et al. (1997). The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A Streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med. 337: 441– 446. 25 Veterans Administration Cooperative Study Group on Antihypertension Agents (1967). Effects of treatment on morbidity in hypertension. I. JAMA. 202: 1028– 1034. 26 Veterans Administration Cooperative Study Group on Antihypertension Agents (1970). Effects of treatment on morbidity in hypertension. II. JAMA. 213: 1143– 1152. 27Fraser, H. S. (1996). Reserpine: a tragic victim of myths, marketing, and fashionable prescribing. Clin Pharmacol Ther. 60: 368– 373. 28Girard, D. Z. (2000). Intervention times series analysis of pertussis vaccination in England and Wales. Health Policy. 54: 13– 25. 29Gerson, W. T., Fine, D. G., Spielberg, S. P. and Sensenbrenner, L. L. (1983). Anticonvulsant-induced aplastic anemia: increased susceptibility to toxic drug metabolites in vitro. Blood. 61: 889– 893. 30Shear, N. H., Spielberg, S. P., Grant, D. M., Tang, B. K. and Kalow, W. (1986). Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med. 105: 179– 184. 31Rieder, M. J., Shear, N. H., Kanee, A., Tang, B. K. and Spielberg, S. P. (1991). Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther. 49: 13– 17. 32Shear, N. H., Spielberg, S. P., Grant, D. M., Tang, B. K. and Kalow, W. (1988). Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med. 105: 179– 184. 33Spielberg, S. P. (1996). Pharmacogenetics and blood dyscrasias. Eur J Haematol Suppl. 60: 93– 97. 34Hedenmalm, K. and Spigset, O. (2002). Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole). Eur J Clin Pharmacol. 58: 265– 274. 35Kaufman, D. W., Kelly, J. P., Levy, M. and Shapiro, S. (1991). The drug etiology of agranulocytosis and aplastic anemia. Oxford University Press: New York. 36Edwards, J. E. and McQuay, H. J. (2002). Dipyrone and agranulocytosis: what is the risk? Lancet. 360: 1438. 37Schönhöfer, P., Offerhaus, L. and Herxheimer, A. (2003). Dipyrone and agranulocytosis: what is the risk? [letter] Lancet. 361: 968– 969. 38Ehsanullah, R. S., Page, M. C., Tildesley, G. and Wood, J. R. (1988). Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ. 297: 1017– 1021. 39Robinson, M. G., Griffin, J. W., Jr, Bowers, J., Kogan, F. J., Kogut, D. G. and Lanza, F. L., et al. (1989). Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis Sci. 34: 424– 428. 40Graham, D. Y., White, R. H., Moreland, L. W., Schubert, T. T., Katz, R. and Jaszewski, R., et al. (1993). Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann Intern Med. 119: 257– 262. 41Laporte, J. R., Carne, X., Vidal, X., Moreno, V. and Juan, J. (1991). Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Lancet. 37: 85– 89. 42Rodriguez, L. A. G. and Hernandez-Diaz, S. (2001). Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology. 12: 570– 576. 43Hernandez-Diaz, S. and Rodrigues, L. A. G. (2000). Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation. Arch Intern Med. 160: 2093– 2099. 44Biour, M., Blanquart, A., Moore, N., Grange, J. D., Amiot, X. and Levy, V. G., et al. (1987). Incidence of NSAID-related, severe gastrointestinal bleeding [letter]. Lancet. 2: 340– 341. 45Carson, J. L., Strom, B. L., Soper, K. A., West, S. L. and Morse, M. L. (1987). The association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding. Arch Intern Med. 146: 85– 88. 46Andrade, S. E., Martinez, C. and Walker, A. M. (1998). Comparative safety evaluation of non-narcotic analgesics. J Clin Epidemiol. 51: 1357– 1365. Citing Literature Volume74, Issue3September 2003Pages 197-202 ReferencesRelatedInformation
Referência(s)